London’s biopharma-focused GHO Capital Partners claims close of largest-ever European fund

November 20, 2019 07:23 AM ESTUpdated 10:45 AM

London's biopharma-focused GHO Capital Partners claims close of largest-ever European fund

Natalie Grover

Reporter

Three years after closing out its first €660 million ($730.5 million) private equity fund, London-based GHO Capital Partners has sealed a mammoth $1 billion-plus second fund, a feat it has claimed is the biggest-ever focused on European healthcare.

The investment firm has already injected capital into active pharmaceutical ingredient manufacturer Sterling Pharma Solutions and bioanalytical testing company BioAgilytix in the first quarter of 2019. GHO’s Fund II will invest in the outsourced services, pharma and medtech sectors, the company said on Wednesday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.

Dr. Gabriel Kremmidiotis, Chief Scientific Officer (center) heads up the biotech ClinicReady team of scientific and medical affairs specialists with a 20-year track record. Dr. Jorgen Mould Avance Clinical Scientific Affairs Specialist (left) and Yvonne Lungershausen, Avance Clinical’s CEO.

How ClinicReady by Australian CRO Avance Clinical delivers preclinical project management and scientific and regulatory advice to get biotechs into clinic faster.

Gabriel Kremmidiotis

Chief Scientific Officer, Avance Clinical

Avance Clinical has formed a dedicated scientific and regulatory affairs service, ClinicReady by Avance Clinical, in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.

The highly regarded Avance Clinical scientific and regulatory team, which has been advising biotech clients on their drug development for more than 20 years, is now a dedicated ClinicReady service under the Avance Clinical banner.

Hans Schambye

September 28, 2020 05:48 AM EDT

Venture

Galecto reaps $64M to bring lead drug across IPF finish line, while making moves in NASH and beyond

Amber Tong

Editor

Back in 2018, Hans Schambye raised $90 million to kick off a late-stage trial that could put Galecto Biotech’s lead drug on the final stretch toward approval for idiopathic pulmonary fibrosis. Two years later, he’s collected another $64 million to complete it.

The Copenhagen-based company has managed to continue recruitment for the 450-patient trial in spite of the pandemic, the CEO told Endpoints News, with data expected by the middle of 2022.

FDA chief Stephen Hahn on Capitol Hill earlier this week (Getty Images)

September 25, 2020 10:56 AM EDTUpdated 19 hours ago

Regulatory

Coronavirus

As FDA’s workload buckles under the strain, Trump again accuses the agency of a political hit job

Arsalan Arif

Publisher & Founder

Peter Marks appeared before a virtual SVB Leerink audience yesterday and said that his staff at FDA’s CBER is on the verge of working around the clock. Manufacturing inspections, policy work and sponsor communications have all been pushed down the to-do list so that they can be responsive to Covid-related interactions. And the agency’s objective right now? “To save as many lives as we can,” Marks said, likening the mortality on the current outbreak as equivalent to “a nuclear bomb on a small city.”

ENDPOINTS CAREERS

Clinical Operations Lead

Vigeo Therapeutics

Cambridge, MA

view job offer post your job now

Minoryx and Sperogenix ink an exclusive license agreement to develop and commercialize leriglitazone in China

Pharmcube

September 23, 2020 – Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain)

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition

David Berry (Flagship)

September 24, 2020 06:03 AM EDTUpdated 07:25 AM

Venture

Startups

Flagship's next big technological bet? The cloud

Jason Mast

Associate Editor

Earlier this month, Flagship announced their big bet on the software half the industry is talking about, launching the AI and machine learning startup. Now, they and a couple other investors are gambling $100 million on a software that much of the public generally thinks of as a cool, IT afterthought: cloud computing.

The idea, says founder and Flagship partner David Berry, is one of scale: The sheer magnitude of biological data that you can store on cloud technology is unprecedented. And that size, when leveraged properly, can allow you to ask questions and form insights that are similarly unprecedented.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.

Patrick Enright, Longitude co-founder (Longitude)

September 23, 2020 07:31 AM EDTUpdated 09:43 AM

Venture

As its biotechs hit the pandemic exit, Longitude raises $585M for new neuro, cancer, aging and orphan-focused fund

Jason Mast

Associate Editor

The years have been kind to Longitude Capital. This year, too.

A 2006 spinout of Pequot Capital, its founders started their new firm just four years before the parent company would go under amid insider trading allegations. Their first life sciences fund raised $325 million amid the financial crisis, they added a second for $385 million and then in, 2016, a third for $525 million. In the last few months, the pandemic biotech IPO boom netted several high-value exits from those funds, as Checkmate, Vaxcyte, Inozyme and Poseida all went public.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,600+ biopharma pros reading Endpoints daily — and it's free.

Image credit: AP

September 25, 2020 11:14 AM EDTUpdated 42 minutes ago

IPOs

The window is wide open as four more biotechs join the go-go IPO class of 2020

Max Gelman

Associate Editor

It’s another day of hauling cash in the biopharma world as four more IPOs priced Friday and a fifth filed its initial paperwork.

The biggest offering comes from PMV Pharma, an oncology biotech focusing on p53 mutations, which raised $211.8 million after pricing shares at $18 apiece. Prelude Therapeutics, developing PRMT5 inhibitors for rare cancers, was next with a $158 million raise, pricing shares at $19 each. Graybug Vision raised $90 million after pricing at $16 per share for its wet AMD candidates, and breast cancer biotech Greenwich Lifesciences brought up the rear with a small, $7 million raise after pricing shares at $5.75.

ENDPOINTS CAREERS

Director of Regulatory Affairs

Recursion Pharmaceuticals

Salt Lake City, UT

view job offer post your job now

September 25, 2020 10:37 AM EDT

Coronavirus